Eli Lilly ( LLY -1.72%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

Eli Lilly will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

Top 10 Stocks. In this article, we are going to take a look at where Eli Lilly And Co (NYSE:LLY) stands against other stocks ...

Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...

Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...

As the project moves forward here is some basic information about the company and the proposed $3 billion development itself.

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

Lepodisiran sodium is an antisense rnai oligonucleotide commercialized by Eli Lilly and Co, with a leading Phase III program in Atherosclerosis.